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Abstract: South Korea operates a National Vaccine Injury Compensation Program (VICP) for people
who experience adverse events following immunization (AEFI). To run this program rationally, it
is a prerequisite to confirm whether adverse events were caused by immunization. Guillain–Barré
syndrome (GBS), a severe neurological disease with limb pain and muscle weakness as cardinal
symptoms, is attracting attention as an AEFI. However, algorithm or guidelines for assessing the
causality between vaccination and the incidence of GBS are lacking. We aimed to develop guidelines
for causality assessment of GBS as an AEFI and suggest using these guidelines in alignment with the
VICP. We systematically searched for other previously published algorithms or guidelines and found
a WHO-AEFI guideline used worldwide; however, it only provides general instructions and is not
tailored to specific adverse events. We translated and locally adapted the structure of this guideline
and then added contents related to GBS. The GBS-specific guideline consists of four steps: case
ascertainment of GBS, checklist (including (1) order of incidence, (2) temporal proximity, (3) evidence
for other causes and (4) published evidence), an algorithm, and final classification. We listed key
information on confirming GBS and whether any other causes of GBS were present. For real world
application of the guideline along with the VICP, we collaborated with a panel of neurologists,
epidemiologic investigators, and committee members from the VICP. To ensure transparency and a
scientific approach, regular updates and collaboration with neurologists are essential. We expect that
this guideline will contribute to logical causality assessment and compensation decisions for GBS and
will provide the basic structure for causality assessment of other AEFIs.
Keywords: adverse event; causality assessment; guideline; Guillain–Barré syndrome; vaccine
1. Introduction
South Korea’s national Vaccine Injury Compensation Program (VICP) is implemented by the
Korea Centers for Diseases Prevention and Control (KCDC) for damage associated with adverse events
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following immunization (AEFI) and is covered by the National Immunization Program (NIP) [1].
Adverse events (AEs) following immunization are defined as any untoward medical occurrences that
follow immunization and do not necessarily have a causal relationship with the vaccine usage [2].
To compensate medical and/or financial damage following vaccination, it is necessary to that the
AEFI were caused due to vaccination. If the causality assessment is not scientific or objective,
the assessment results will be inconsistent, and consequently the compensation program will no longer
have credibility. Thus, it is crucial to have a valid causality assessment system for better operation of
the compensation program.
There are a number of causality assessment tools for AEs caused by drugs, including the World
Health Organization–Uppsala Monitoring Center (WHO-UMC) system [3,4], Naranjo algorithm [5],
Modified Kramer Method [6], Roussel Uclaf Causality Assessment Model (RUCAM) algorithm [7],
and Alden algorithm [8]. By comparison, a systematic review has identified only one tool for causality
assessment of vaccines, developed by the World Health Organization (WHO). This user manual was
developed in 2013, and the second edition was published in 2018 [9]. According to the WHO, it was
intended to be used by staff at national and subnational levels (such as members of the national AEFI
committee or immunization program managers) as a guide to a systematic and standardized global
causality assessment process for individual serious AEFI [9]. The WHO user manual provides useful
guidelines for causality assessment of AEFI and presents the following standardized steps: eligibility,
checklist, algorithm, and classification. However, they are general guidelines for all types of AEFI
and not specific to individual types of AEFI. The types and strength of evidence and factors needed
for causality assessment may be different depending on the type of AEFI. AEFI-specific causality
assessment guidelines would be helpful for conducting more accurate causality assessments.
Therefore, our study aimed to develop AEFI-specific causality assessment guidelines using the
basic framework suggested by the WHO manual. In particular, we developed causality assessment
guidelines for Guillain–Barré syndrome (GBS), a severe neurological AEFI, with limb pain as the major
symptom [10]. GBS is not a common AEFI but has received special attention due to the seriousness
of its symptoms and sequelae. The background incidence of GBS is estimated at 0.8–1.9 per 100,000
person-years and increases with age [11]. The incidence of GBS following vaccination varies according
to the flu season, and it is known that an additional 1 to 2 cases of GBS occur after 1 million doses of
the influenza vaccine [12]. Although we developed these guidelines in Korea, we expect they will be
generalizable to other countries because they were developed on the basis of the WHO framework and
international literature and evidence.
2. Materials and Methods
We developed the causality assessment guidelines for GBS following immunization in two steps:
local adaptation of the global WHO guidelines and development of GBS-specific guidelines (Figure 1).
2.1. Local Adaptation of the Global WHO Guidelines
First, we translated the “Annex 1: Worksheet for AEFI causality assessment” from the second
edition of the WHO user manual for AEFI causality assessment [9] into Korean and developed a draft
Korean version. We followed the same structure of steps for causality assessment of an individual AEFI
included in the WHO manual. They are as follows: eligibility, checklist, algorithm, and classification.
All items presented with these steps were incorporated.
Eligibility (step I) aims to determine if the AEFI case satisfies the minimum criteria for causality
assessment. Questions to ascertain the eligibility include “Was the vaccine administered before the
event occurred?”, “What is a valid diagnosis?”, and “Did the diagnosis meet a case definition?” In step I,
the investigator is also asked to create his or her question on causality such as “Has the vaccine A caused
GBS?” Checklist (step II) involves systematically reviewing the relevant and available information to
address possible causal aspects of the AEFI. Questions included in the checklist are as follows: “Is
there strong evidence for other causes?”, “Is there a known causal association with the vaccine or
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vaccination?”, ‘Was the event within the time window of increased association risk?’; “Is there strong
evidence against a causal association?”, and “Are there other qualifying factors for classification?”
Some of the question categories also consist of detailed sub-questions. An Algorithm (step III) identifies
whether there is a trend suggesting causality using the information gathered in the checklist. On the
basis of the trend determined in the algorithm, classification (step IV) categorizes the AEFI association
with the vaccine, or vaccination, into four categories. A case with adequate information for a causality
conclusion can be classified as one of the following three categories: consistent causal association with
immunization, indeterminate, and inconsistent causal association with immunization (coincidental).
A case without adequate information could additionally be classified as “unclassifiable”.
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Second, for the local adaptation of the WHO manual, we conducted two-stage pilot tests with
Epidemiology Intelligence Service (EIS) officers. Because EIS officers are in charge of collecting detailed
information about the AEFI as the initial step of the VICP (e.g., patient history and physical findings)
and are responsible for filling out the checklist from the guidelines, we considered that their feedback
was crucial in developing a locally adoptable guideline. As the first stage, we conducted an in-depth
interview with two EIS officers (one had many years of experience as an EIS officer and the other
was a pediatric specialist) to collect unstructured feedback on the draft of the translated guideline.
This focused on the structure of the guideline, terminology, appropriateness, and feasibility of the
individual items included in the draft. Based on their feedback, we revised the draft. In the second
stage, we conducted a pilot test of the revised Korean version with seven EIS officers, who attended a
Vaccine Injury Investigation Unit (VIIU) meeting during the study period. We asked the participants to
apply the draft Korean version to AEFI cases that the Vaccine Injury Compensation Expert Committee
(VICEC) had previously reviewed. Based on their feedback about the readability, appropriateness, and
feasibility of individual items and their overall opinions, a further revision was made, and the general
causality assessment guidelines were finalized.
2.2. Development of GBS-Specific Guidelines
From the Korean version of the general guidelines, we developed a set of items tailored to GBS
cases. GBS is a neurological disorder accompanied by paralysis, and a precise diagnosis is a paramount
first step in causality assessment because many diseases have similar symptoms. We first defined
GBS using the Brighton Collaboration (BC) criteria [2]. Subsequently, further questions aimed at
ascertaining a GBS diagnosis were developed by reviewing previous studies [13–15] and the medical
records attached to GBS cases previously identified as AEFI, which had been reported to the VIIU.
We then focused on the assessment of temporal proximity and other known causes of GBS. In
order to develop evidence-based items, we conducted a systematic literature review (Supplementary
S1). We also examined all previous reports to the VIIU as well as the results of the VICEC’s causality
assessment for GBS and extracted suspected individual causes of GBS. Then, we qualitatively
synthesized evidence and references as a result of the quality assessment by 10 neurologists
(Supplementary S2). Finally, by customizing all remaining items in the checklist, the first draft
of the GBS-specific causality assessment guideline was complete. Next, we proceeded to ask three
neurologists about the clinical validity of the first draft again. Based on their feedback, we revised the
guidelines and prepared the second draft. We then asked seven epidemiologists about its feasibility of
the second draft. The third draft of the GBS-specific guidelines was then applied in an actual meeting
of the VIIU as a pilot test, and the final version was completed by reflecting on feedback from the
committee members of the pilot test.
3. Results
3.1. Structure of the Guidelines
The guidelines developed in the present study are based on the structure of the WHO AEFI
guidelines and includes the following: case ascertainment of GBS; checklist for causality assessment
composed of (1) order of incidence, (2) temporal proximity, (3) grounds for other causes, and (4)
published evidence; causality assessment algorithm; and final classification (Figure 2).
3.2. Case Ascertainment of GBS (Eligibility)
Case ascertainment of GBS is not a part of causality assessment, but it is an important prerequisite
task that triggers causality assessment. Diagnosis of GBS is confirmed by G61.0 of ICD-10th code
and BC criteria (Table 1). These are sets of standard diagnostic criteria for GBS that use 4 levels of
classification, with “level 1” indicating the highest level of diagnostic certainty (definite). For each
patient with GBS, the reviewer fills in the corresponding checkboxes for each criterion and decides
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the level of diagnostic certainty. Since it is not routine clinical practice to collect all the information
included in BC criteria, depending solely on these criteria to ascertain GBS is unrealistic. Therefore,
our study developed additional questions to help with diagnosis: “Was the paralysis ascending?” and
“Did it take less than 4 weeks for symptoms to stop worsening?” (Table 1). The more questions that are
answered with “Yes”, the more likely the diagnosis of GBS is correct. We also added four questions
that might indicate diseases other than GBS. For these questions, the more questions that are answered
with “Yes”, the less likely the diagnosis of GBS is correct.
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Table 1. Case ascertainment of Guillain–Barré syndrome.
1. Diagnostic code
ICD-10th code
2. Brighton Collaboration criteria *
No. Brighton Collaboration criteria Y N NA/UJ
2.1. Bilateral AND flaccid weakness of the limbs
2.2 Decreased or absent deep tendon reflexes in weak limbs
2.3. Monophasic illness pattern AND interval between onset and nadir of weaknessbetween 12 h and 28 days AND subsequent clin cal plateau
2.4. Absence of an identified alternative diagnosis for weakness
2.5. Cytoalbuminologic dissociation (i.e., elevation of CSF protein level above normalvalues AND CSF total white cell count <50 cells/µL)
2.6. Electrophysiologic findings consistent with GBS
• All “Yes” for 2.1.-2.4. ⇒ Level 3
• All “Yes” for 2.1.-2.4. and for 2.5. or 2.6. ⇒ Level 2
• All “Yes” for 2.1.-2.6. ⇒ Level 1
• None of the above⇒ Unable to distinguish
Brighton Collaboration diagnostic level result
3. Questions to help diagnosis
No. Examinations to diagnose Guillain–Barré syndrome Y N NA Note
3.1. Was a test for nerve conduction performed? Write the date of the test andspecifics in the note column.
3.2. Was a test for cerebrospinal fluid performed? Write the date of the test andspecifics in the note column.
Questions to help diagnose Guillain–Barré syndrome Y N NA UJ Note
3.3. Was the paralysis ascending?
3.4. Did it take less than 4 weeks for symptoms to stop worsening?
Questions that might indicate diseases other than Guillain–Barré syndrome
3.5. Were the symptoms accompanied by cognitive deterioration?
3.6. Did the initial symptoms include fever?
3.7. Did the initial symptoms include bowel or bladder dysfunction?
3.8. Was there any other cause of muscular weakness or paralysis?
* Brighton Collaboration criteria for Guillain–Barré syndrome is quoted and reconstructed from Definition and
Application of Terms for Vaccine Pharmacovigilance by Report of CIOMS/WHO Working Group on Vaccine
Pharmacovigilance in 2012 on pages 84–85. Y, Yes; N, No; NA, Not applicable; UJ, Unable to judge.
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3.3. Checklist
To address the possible causal relationship between vaccination and GBS, a number of questions
were included in the checklist (Table 2). Questions were grouped into the following four themes:
order of incidence, temporal proximity, evidence for other causes, and published evidence of a causal
association. Order of incidence asks whether the vaccine was administered before GBS onset. Temporal
proximity intends to confirm whether GBS occurred within a plausible time window after vaccine
administration. According to a literature review, the incidence of GBS occurring within 6 weeks
following immunization is considered to have causality with the vaccination [16,17].
To examine the evidence against a causal association, questions regarding various causes other
than the vaccine were included in the checklist. As a first step, the patient’s GBS and vaccination
history were reviewed. Reviewing patient’s history helps decide whether this occurrence of GBS is
due to vaccination, or whether other causes should be investigated.
Based on a literature review and consultation with the clinician panel, we found that several
conditions are known to cause GBS [18]. These include upper respiratory infection [18–21],
gastrointestinal disorders [18–20,22], Zika/Dengue infection [23], Malaria infection [24,25],
Tsutsugamushi infection [26], surgery history [27,28], campylobacter infection [29–34], cytomegalovirus
infection [33–38], Epstein–Barr virus infection [33,38–41], herpes simplex virus [39], varicella-zoster
virus infection [42], mycoplasma pneumonia infection [43,44], haemophilus influenza infection [18,45],
and influenza virus infection [46,47]. For each condition, the checklist asks whether the patient had
the condition prior to the manifestation of GBS. Most members of the clinical panel agreed that the
chosen time window of 6 weeks was appropriate for assigning a causal association of GBS with prior
infections. Our guideline provides instructions to write the date of prior infections in the note column
of the checklist.
In the last part of the checklist, the guideline provides up-to-date published evidence about
the causal association between various vaccines and GBS. The vaccines included are influenza,
meningococcal, MMR, polio, HPV, hepatitis A, hepatitis B, and varicella vaccine. The evidence could
either support or oppose the causal association. For each vaccine, the most up-to-date evidence should
be provided, so that the causality assessment is performed on the basis of the most current evidence.
3.4. Algorithm and Classification
Based on the information collected in the checklist, the reviewer answers each of the five questions
included in the causality assessment algorithm as “Yes” or “No” (Figure 3). The first question was
numbered as “0” because a valid diagnosis of GBS is a pre-requisite condition to proceed with the
causality assessment algorithm. As the number of questions with positive answers (“Yes”) for the
causal association increases, causality between the vaccination and GBS increases. As an exception, a
negative answer (“No”) to the question “Does the evidence for other causes work against a causal
association between the vaccination and GBS?” is considered as a positive answer. For all questions,
we are required to provide explanation for a positive or negative answer.
The last step is to classify the extent of GBS’s association with the vaccine, or vaccination, on the
basis of the trend determined by the algorithm and to arrive at a decision on causality. The extent of the
causal association is classified into the following five categories: “definitely related,” “probably related,”
“possibly related,” “unlikely related,” and “definitely not related.” The framework of this classification
follows that of the pre-existing framework by the Korean VICP. A separate classification expressed
as “indeterminate” is also included. After completing the checklist and using the algorithm, the
reviewer may discover that the information gathered is not sufficient to arrive at a definite conclusion.
As such, the case can be classified as “indeterminate,” and requires the reviewer to specify the missing
information that prevents the classification of the case. Detailed criteria for each classification are
presented in Figure 4.
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Table 2. Causality assessment guidelines for Guillain–Barré syndrome following immunization: Checklist.
1. Order of the incidence
◦ Was the vaccine administered before Guillain–Barré syndrome
occurred? Yes/No
2. Temporal proximity (time interval)
◦ Did Guillain–Barré syndrome occur within 6 weeks following
vaccination? Yes/No
◦Write the time interval between vaccination and the occurrence of
Guillain–Barré syndrome (e.g., 4 weeks following vaccination).
3. Evidence for other causes
◦ For each question, please answer Y(=Yes), N(=No), UK(=Unknown) or NA(=Not applicable).
◦ Please write the reason for your answer in the note column.
Y N UK NA Note
History *
3.1 Has the patient ever experienced
Guillain–Barré syndrome or other
neuromuscular disorders regardless of
vaccination? Please write the name of the
disease in the note column.
3.2. Has the patient ever been vaccinated with
the same vaccine in the past? If so, please write
the vaccination date.
3.3. Has the patient ever experienced
Guillain–Barré syndrome or any other





◦ Has the patient ever experienced any items listed below before the manifestation of Guillain–Barré syndrome? If so,
please write the date of the infection.
3.4. Upper respiratory infections
3.5. GI troubles






◦ Was a test for any pathogens listed below performed after the manifestation of Guillain–Barré syndrome? If so,
write the date of the test, test result, and specific notes.
3.10. Campylobacter jejuni
3.11. Cytomegalo virus (CMV)
3.12. Epstein-Barr virus (EBV)
3.13. Herpes Simplex virus (HSV)







3.19. Was the Guillain–Barré syndrome a stress
response to vaccination? (e.g., acute stress
response, vasovagal syncope, hyperventilation,
anxiety, etc.)
Vaccine quality
3.20. Could the vaccine given to this patient




type of error, if
any)
3.21. Did anything unusual occur during
vaccination preparation? (e.g., incorrect mixing,
use of expired vaccine, abnormal physical
condition, etc.)
3.22. Did anything unusual occur during the
vaccination procedure? (e.g., Inoculation
timing/dose/site/route, needle size error, etc.)
◦ If there are any suspicious causes other than those listed above, write the details below.
◦ Other causes











WHO GACVS, WHO Global Vaccine Safety; IOM, Institute of Medicine. * The time window between prior infection
and vaccination was considered as 6 weeks based on a literature review and expert survey.
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3.5. Application
We recommend that the guidelines developed in this study should be used to assess causality in
the VICP in Korea as follows. First, when GBS is reported as an AEFI, the EIS officer who is in charge
of collecting basic information about the AEFI, fills out the checklist as the first official step of the VIIU.
Second, the Investigation Committee of the VIIU reviews the checklist and revises it if necessary. Based
on the revised checklist, the officers use the causality assessment algorithm and determine a draft
classification of the AEFI, according to one of the six categories. Lastly, the VICEC reviews the answers
of each question in the algorithm and the classification drafted by the Investigation Committee on
VIIU and arrives at a decision on causality. Based on the causality decision, the eligibility of AEFI for
compensation is determined.
In addition, the context is important and necessary for the guidelines to be effective. First, the
guidelines developed in this study were based on the most recent literature and scientific evidence
available at the time of the study. To maintain the effectiveness of the guidelines, we recommend
that the VIIU continues to collect new evidence, establishes a database of the evidence, and regularly
updates the guidelines. Second, EIS officers play a significant role in ensuring the guidelines perform as
intended. This is because they are at the forefront in collecting information about AEFI from the clinical
field; therefore, they can provide the key information for causality assessment. Furthermore, they are
the first people who fill out the checklist, which is the starting point of the causality assessment process.
Thus, EIS officers should undergo proper training on how to use the guidelines. Establishing a database
for the literature on the association of GBS with vaccination and continuous updating of this database
will be crucial in helping EIS officers to perform their duties efficiently. Third, unlike other types of
AEFI, neurologic AEs, such as GBS, are challenging in terms of achieving valid diagnoses due to the
nature of symptoms and clinical features. In the process of guideline development, consultation with
neurologists was crucial in developing checklist items used to ascertain GBS. Therefore, we recommend
that the VIIU utilize a consultation panel composed of neurologists who will be actively involved
throughout the causality assessment process.
4. Discussion
4.1. First Guidelines for Causality Assessment between Guillain–Barré Syndrome and the Vaccine
Following Vaccination
This study was conducted to contribute to objective and valid causality assessment by developing
guidelines to assist in determination of causality between GBS and vaccination. The WHO AEFI
guidelines were developed as a tool to assess the causality of AEFI; however, they are insufficient
for assessing individual AE because they only present the overall framework and flow. Pathological
mechanisms of action, as well as the relationship between the patient’s underlying disease and an
AE, should be closely examined to determine causality. Accordingly, effective guidelines for the
causality assessment of AEFI must include items related to the specific AE; thus, there is a need for
causality assessment guidelines for AEs according to type. Indeed, in the case of drugs, the WHO-UMC
guidelines are used as an overall assessment tool to assess an AE that occurred after drug administration.
Additional guidelines are used to determine causality between the drug treatment and liver injury or
Stevens–Johnson syndrome (SJS), both serious AEs of interest [7,8,48]. Liver injury is a known AE
related to cytochrome P450, a liver enzyme involved in the metabolism of many drugs [49,50] and
the immune response [51], and SJS is a life-threatening, intolerance reaction of the skin [52]. As such,
the factors to be confirmed to determine the causality of drugs vary greatly depending on the diseases
involved, as well as the symptoms, diagnosis, pathogenesis, and relevance to the drugs administered.
Similarly, disease-specific causality assessment tools for AEs that occur after vaccination are necessary.
The significance of this study lies in the development of a disease-specific causality assessment tool
for GBS, one of the most notable AEFI, by using the basic framework of WHO AEFI guidelines that
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have already been tested. Our approach to developing a causality assessment guideline for a specific
disease is expected to be generalizable to the causality assessment of other AEFI.
4.2. Securing the Objectivity of the Clinical Diagnosis of Guillain–Barré Syndrome through
Multi-Step Verification
Case ascertainment of GBS is a necessary prerequisite before we proceed causality assessment.
However, GBS is a difficult disease to arrive at a differential diagnosis. This is due to the key symptoms
of paralysis and muscular weakness that are present in other neurological diseases and the fact
that a range of causes have been identified. Therefore, in this study, we developed a checklist for
accurate diagnosis by using the diagnostic code from the ICD-10th, prescription details, the BC criteria,
and existing damage compensation reports to secure the diagnostic objectivity of GBS. In addition,
an advisory panel of 10 neurologists was formed, and surveys were conducted twice to test the validity
of the list. As a result, a list that can help to accurately diagnose GBS was developed by combining
laboratory data and clinical evaluation. The items included in the list and the process of developing
it are expected to be used not only in these guidelines but also for the objective diagnosis of similar
neurological diseases in the future.
4.3. Recommended Application Method of Guidelines Aligned with Policy
The NIP is implemented as a part of national policy. Consequently, in South Korea, if a person
vaccinated through the NIP experiences an AE, the government assesses causality between the AE and
the vaccine and determines the level of damage compensation [53,54]. Institutional frameworks and
expert committees have already been established in an attempt to maintain the consistency, objectivity,
and validity of assessment. However, in cases that required a significant number of professional
opinions from diagnosis to determination of the cause, such as GBS, ensuring the consistency of
assessment results has been difficult. Thus, our guidelines were developed in association with
epidemiologists and the committee, and an application system was proposed to ensure that the
guidelines can be used effectively in the actual compensation policy. This indicates that the results
of this study can continue to be used, and the guidelines can be immediately implemented in the
actual policy. Furthermore, the guidelines are expected to play a role in filling the gaps between
stages that may occur in the current compensation system (by the epidemiological survey, the damage
investigation team, and the damage compensation committee).
For the guidelines to be properly used, the collection of patient’s medical records, an interview
with the physician in charge, and a patient history taken by an epidemiologist are all of paramount
importance. This allows confirmation of diagnosis of GBS and gathers additional information
to determine whether the AE was triggered by causes other than the vaccination [20]. To this
end, the government should organize systematic and specialized curricula and regularly provide
epidemiologists with the results of epidemiologic investigations, so that results do not depend on the
ability of the individual epidemiologist. Furthermore, academics should prepare standard guidelines
to diagnose GBS and actively promote them to neurologists, so that GBS can be diagnosed using the
same criteria. If the government, with the support of academia, can establish a system to regularly
search for and incorporate new evidence, the use of GBS guidelines may be increased.
This study has some limitations; therefore, cautious interpretation and application are needed.
First, the guidelines were developed based on the most recently published evidence at this time.
This means unknown factors that cause GBS may remain obscure and undetected. Systematic support
will be needed to continuously update these guidelines to include new research in a timely matter.
Second, it is difficult to determine if a patient has had a prior infection that may have caused the
GBS, increasing the possibility that causality may be incorrectly attributed to the vaccine. Because
there is often a time lag between a potential infectious (or vaccine) trigger and the actual occurrence
of GBS, this makes it difficult to tell with certainty whether or not an infectious cause could be ruled
out. Although we developed these guidelines to collect comprehensive information related to GBS
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outbreaks, clinical judgments ultimately belong to experts, and only experts can assess the factors to
make decisions. To properly use these guidelines, participation of clinical experts is crucial. Therefore,
we suggest appropriate education and active promotion of the guidelines.
5. Conclusions
Causality assessment of AEFI is crucial not only to counteract vaccine hesitancy, but also to
implement an evidence-based national vaccine policy. Since each AEFI has distinct characteristics,
the demand for developing a condition-specific causality assessment guideline is of great need.
Our approach to developing the GBS-specific guideline suggests a transparent and scientific process
and provides the basic structure applicable to causality assessment of other AEFIs. If the systematic
regular updates by clinical experts and the support by the government are sustained, the GBS-specific
guideline developed in our study can be used effectively in the actual vaccine policy.
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